TRIAL DETAIL

Study of BMS-354825 in Patients With Solid Tumors

Drug:
Trial Name:
Study of BMS-354825 in Patients With Solid Tumors
NCT#:
Conditions:
Tumors
Status:
Completed
Phase:
1
Start Date 01/01/2007
Age of Trial (yrs) 15.9
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + SRC inhibitor
Strategy:
Block KIT + Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CA180-058
Sponsor:
Bristol-Myers Squibb
Patient Contact:
Local Institution, Koto-Ku, Tokyo
Contact email:
Clinical.Trials@bms.com
Contact Phone:
135-0063
Randomized:
IV or Oral:
Oral
Trial Notes:
Study chairs or principal investigators

Taku Seriu, MD, PhD, Study Director, Bristol-Myers Squibb
Please refer to this study by ClinicalTrials.gov identifier NCT00339144

For participation information at a USA site use a phone number below. For site information outside the USA please email: Clinical.Trials@bms.com
First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.

Trial Links

 

Trial Results

Drug Information

Dasatinib inhibits KIT D816V mutation-an imatinib-resistant activating mutation
 
Sprycel.com
 
Sprycel reimbursement support (Destination Access)
 
Sprycel prescribing information (PDF)
 
Dasatinib inhibits PDGFRA D842V mutation - Debiec-Rychter - 2008
 
Dasatinib inhibits activity of wild-type, juxtamembrane and activation loop mutant KIT (Heinrich, et al)
 
FDA drug information page (technical information about the drug approval, etc)
 
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib (mentions that dasatinib levels are highly affected by PPIs).
 
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
 
FDA: Increased Pulmonary Arterial Hypertension Risk Seen With Dasatinib
 
FDA website: Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension
 
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities
 
Disintegration of chemotherapy tablets (including dasatinib) for oral administration in patients with swallowing difficulties
 
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
 

Trial Sites

Name
Address
City
State
Zip
Country
Tokyo
135-0063
Japan
Osaka
589-014
Japan